Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens

Arch Pathol Lab Med. 2018 Mar;142(3):364-368. doi: 10.5858/arpa.2017-0014-OA. Epub 2017 Nov 16.

Abstract

Context: - The Ki-67 index is strongly prognostic and is used as a surrogate marker to distinguish luminal A from luminal B breast cancer types.

Objective: - To investigate differences in Ki-67 index between core needle biopsy samples and matched surgical samples in breast cancer.

Design: - We included patients with invasive breast cancer who did not receive neoadjuvant therapy. A total of 89 pairs of core needle biopsies and surgical specimens were collected, and the Ki-67 index was assessed in hot spot areas using an image analyzer. We applied a 14% Ki-67 index to define low versus high groups.

Results: - The Ki-67 index was significantly higher in core needle biopsies than in surgical specimens ( P < .001), with a median absolute difference of 3.5%. When we applied 14% as a cutoff, 16 of 89 cases (18%) showed discrepancy. Thirteen cases showed a high Ki-67 index in core needle biopsies but a low Ki-67 index in surgical samples. There were 10 cases (11.2%) that showed discordant luminal A/B types between core needle biopsy and the matched surgical specimen. The reasons for the discordance were poor staining of MIB1 accompanied by fixation issues and intratumoral heterogeneity of the Ki-67 index.

Conclusions: - A significant difference in the Ki-67 index between core biopsy and surgical specimens was observed. Our findings indicate that it may be better to perform the Ki-67 assay on the core needle biopsy and the surgical specimen than on only one sample.

MeSH terms

  • Biomarkers, Tumor / analysis
  • Biopsy / methods
  • Biopsy, Large-Core Needle / methods
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Ki-67 Antigen / analysis*
  • Reproducibility of Results

Substances

  • Biomarkers, Tumor
  • Ki-67 Antigen